Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

CD276 overexpression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

CD276 expression (8)

CD276 expression (8)

›

CD276 overexpression	Solid Tumor	CD276 overexpression	Solid Tumor	DS-7300 Sensitive: C3 – Early Trials DS-7300 Sensitive : C3	DS-7300 Sensitive: C3 – Early Trials DS-7300 Sensitive : C3
CD276 overexpression	Prostate Cancer	CD276 overexpression	Prostate Cancer	DS-7300 Sensitive: C3 – Early Trials DS-7300 Sensitive : C3	DS-7300 Sensitive: C3 – Early Trials DS-7300 Sensitive : C3
CD276 overexpression	Small Cell Lung Cancer	CD276 overexpression	Small Cell Lung Cancer	DS-7300 Sensitive: C3 – Early Trials DS-7300 Sensitive : C3	DS-7300 Sensitive: C3 – Early Trials DS-7300 Sensitive : C3
CD276 overexpression	Non Small Cell Lung Cancer	CD276 overexpression	Non Small Cell Lung Cancer	DS-7300 Sensitive: C3 – Early Trials DS-7300 Sensitive : C3	DS-7300 Sensitive: C3 – Early Trials DS-7300 Sensitive : C3
CD276 overexpression	Esophageal Squamous Cell Carcinoma	CD276 overexpression	Esophageal Squamous Cell Carcinoma	DS-7300 Sensitive: C3 – Early Trials DS-7300 Sensitive : C3	DS-7300 Sensitive: C3 – Early Trials DS-7300 Sensitive : C3
CD276 overexpression	Non Small Cell Lung Cancer	CD276 overexpression	Non Small Cell Lung Cancer	trametinib Sensitive: D – Preclinical trametinib Sensitive : D	trametinib Sensitive: D – Preclinical trametinib Sensitive : D
CD276 overexpression	Multiple Myeloma	CD276 overexpression	Multiple Myeloma	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D	ruxolitinib Sensitive: D – Preclinical ruxolitinib Sensitive : D
CD276 overexpression	Squamous Cell Carcinoma of Head and Neck	CD276 overexpression	Squamous Cell Carcinoma of Head and Neck	MGC018 Sensitive: D – Preclinical MGC018 Sensitive : D	MGC018 Sensitive: D – Preclinical MGC018 Sensitive : D
CD276 overexpression	Triple Negative Breast Cancer	CD276 overexpression	Triple Negative Breast Cancer	B7-H3-targeted antibody-drug conjugate Sensitive: D – Preclinical B7-H3-targeted antibody-drug conjugate Sensitive : D	B7-H3-targeted antibody-drug conjugate Sensitive: D – Preclinical B7-H3-targeted antibody-drug conjugate Sensitive : D
CD276 overexpression	Solid Tumor	CD276 overexpression	Solid Tumor	GTB-5550 Sensitive: D – Preclinical GTB-5550 Sensitive : D	GTB-5550 Sensitive: D – Preclinical GTB-5550 Sensitive : D
CD276 overexpression	Breast Cancer	CD276 overexpression	Breast Cancer	ITC-6102RO Sensitive: D – Preclinical ITC-6102RO Sensitive : D	ITC-6102RO Sensitive: D – Preclinical ITC-6102RO Sensitive : D
CD276 overexpression	Lung Cancer	CD276 overexpression	Lung Cancer	ITC-6102RO Sensitive: D – Preclinical ITC-6102RO Sensitive : D	ITC-6102RO Sensitive: D – Preclinical ITC-6102RO Sensitive : D